• Je něco špatně v tomto záznamu ?

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

J. Frankum, P. Moudry, R. Brough, Z. Hodny, A. Ashworth, J. Bartek, CJ. Lord,

. 2015 ; 6 (13) : 10746-58.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010320

Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel predictive biomarkers of tumour cell sensitivity to olaparib, it is possible that the utility of PARP inhibitors could be extended beyond this patient subgroup. Many of the known genetic determinants of PARP inhibitor response have key roles in DNA damage response (DDR) pathways. Although protein ubiquitylation is known to play an important role in regulating the DDR, the exact mechanisms by which this occurs are not fully understood. Using two parallel RNA interference-based screening approaches, we identified the E3 ubiquitin ligase, CBLC, as a candidate biomarker of response to olaparib. We validated this observation by demonstrating that silencing of CBLC causes increased sensitivity to olaparib in breast cancer cell line models and that defective homologous recombination (HR) DNA repair is the likely cause. This data provides an example of how defects in the ubiquitin machinery have the potential to influence the response of tumour cells to PARP inhibitors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010320
003      
CZ-PrNML
005      
20160415132034.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.3628 $2 doi
035    __
$a (PubMed)25883215
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Frankum, Jessica $u The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
245    10
$a Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity / $c J. Frankum, P. Moudry, R. Brough, Z. Hodny, A. Ashworth, J. Bartek, CJ. Lord,
520    9_
$a Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By identifying novel predictive biomarkers of tumour cell sensitivity to olaparib, it is possible that the utility of PARP inhibitors could be extended beyond this patient subgroup. Many of the known genetic determinants of PARP inhibitor response have key roles in DNA damage response (DDR) pathways. Although protein ubiquitylation is known to play an important role in regulating the DDR, the exact mechanisms by which this occurs are not fully understood. Using two parallel RNA interference-based screening approaches, we identified the E3 ubiquitin ligase, CBLC, as a candidate biomarker of response to olaparib. We validated this observation by demonstrating that silencing of CBLC causes increased sensitivity to olaparib in breast cancer cell line models and that defective homologous recombination (HR) DNA repair is the likely cause. This data provides an example of how defects in the ubiquitin machinery have the potential to influence the response of tumour cells to PARP inhibitors.
650    _2
$a protein BRCA2 $x genetika $x metabolismus $7 D024682
650    _2
$a nádory prsu $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D001943
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a oprava DNA $7 D004260
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a ftalaziny $x farmakologie $7 D010793
650    _2
$a piperaziny $x farmakologie $7 D010879
650    _2
$a PARP inhibitory $x farmakologie $7 D000067856
650    _2
$a poly(ADP-ribosa)polymerasy $x genetika $x metabolismus $7 D011065
650    _2
$a posttranslační úpravy proteinů $7 D011499
650    _2
$a protoonkogenní proteiny c-cbl $x genetika $x metabolismus $7 D050721
650    _2
$a RNA interference $7 D034622
650    _2
$a rekombinace genetická $7 D011995
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a časové faktory $7 D013997
650    _2
$a transfekce $7 D014162
650    _2
$a ubikvitinace $7 D054875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Moudry, Pavel $u Danish Cancer Society Research Center, Strandboulevarden, Copenhagen, Denmark.
700    1_
$a Brough, Rachel $u The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
700    1_
$a Hodny, Zdenek $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska, Czech Republic.
700    1_
$a Ashworth, Alan $u The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK. $7 gn_A_00009339
700    1_
$a Bartek, Jiri $u Danish Cancer Society Research Center, Strandboulevarden, Copenhagen, Denmark. Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska, Czech Republic.
700    1_
$a Lord, Christopher J $u The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 6, č. 13 (2015), s. 10746-58
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25883215 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160415132119 $b ABA008
999    __
$a ok $b bmc $g 1113749 $s 934688
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c 13 $d 10746-58 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace